This post is from a suggested group
Biopharmaceuticals: The Era of "Living" Medicines
Biopharmaceuticals are medical products manufactured using biological sources (living cells, yeast, or bacteria) rather than chemical synthesis. By 2026, they represent over 40% of all new drug approvals.
Key Innovations in 2026
Monoclonal Antibodies (mAbs): Targeted proteins used for everything from rheumatoid arthritis to specialized cancer immunotherapy.
Cell and Gene Therapies: Treatments like CAR-T cell therapy, where a patient's own cells are "reprogrammed" in a lab to fight disease.
Continuous Manufacturing: Instead of "batch" cooking, 2026 factories use continuous bioprocessing, where the medicine is produced 24/7 in a steady stream, significantly lowering production costs and improving purity.
